Emcure Pharmaceuticals Limited (EMCURE) announced today that Poviztra®, its co-marketed brand of innovator semaglutide (rDNA origin), will now be available for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2-F3), following the Central Drugs Standard Control Organization’s (CDSCO) approval. This approval addresses a significant unmet medical need for patients with MASH, a progressive liver disease with limited treatment options. Poviztra® is manufactured and imported from Novo Nordisk’s European manufacturing facility and contains innovator rDNA-origin semaglutide. Through its subsidiary Zuventus Healthcare’s strong gastroenterology and hepatology portfolio, Emcure will help expand MASH awareness, diagnosis, and treatment.

CDSCO Approval and Clinical Benefits

The approval makes the innovator molecule from Novo Nordisk, the first and only GLP-1 receptor agonist approved in India for the treatment of the disease. It enables Emcure and its subsidiaries to offer the new indication through Poviztra®, expanding access to innovator semaglutide for patients living with a progressive liver disease that has long faced limited treatment options. The approval is supported by results from the global Phase III ESSENCE trial, in which semaglutide demonstrated resolution of steatohepatitis in 63% of patients and improvement in liver fibrosis in 37% of patients. One in three patients achieved both resolution of steatohepatitis and improvement in liver fibrosis, highlighting semaglutide’s potential to address the underlying disease in addition to its established metabolic benefits.

Company’s Commitment to Innovation

Satish Mehta, Chief Executive Officer & Managing Director, Emcure Pharmaceuticals Limited, said: ‘The approval for MASH marks an important milestone for patients living with a serious and often underdiagnosed liver disease. We are pleased to make this important new indication available through Poviztra®, further strengthening our commitment to bringing globally validated, innovative therapies to patients in India. We look forward to working closely with healthcare professionals to improve awareness, encourage earlier diagnosis, and expand access to evidence-based treatment for people living with MASH.’ The addition of the MASH indication for Poviztra® further strengthens the company’s commitment to addressing complex metabolic diseases through innovative, science-led therapies while supporting physicians in improving long-term patient outcomes.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Emcure holds in the upper half of its 52-week range, a sign the market backs the stock. The business compounds revenue at 15.8% and profits at 20.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 76% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The business grows revenue at 15.8% and profits at 20.2%, with D/E of 0.22. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 1.81 premium is usually justified. Check Fundamentals of Emcure Pharmaceuticals Limited.

Emcure Pharmaceuticals Limited (NSE: EMCURE) today announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited (“Gennova”), alongside a leadership transition, as it sharpens its focus as a biologics and biosimilars company. Emcure is acquiring the entire 12.05% minority stake in Gennova held by Dr. Sanjay Singh and others, taking its ownership to 100% and making Gennova a wholly owned subsidiary.

Leadership Transition

Gennova will be led by Mr. Samit Mehta and will focus on its biologics franchise — Elaxim®/TENECTASE®, Vintor®, Xgrast®/PEGEX® and Hamsyl® — biosimilars development, and adjacent therapeutic platforms, leveraging its established mammalian and microbial biomanufacturing platforms.

Strategic Focus

Commenting on the announcement, Mr. Satish Mehta, Managing Director & CEO, Emcure Pharmaceuticals Limited, said: “We thank Dr. Sanjay Singh for his nearly two decades of exceptional scientific leadership at Gennova. His stewardship has built platforms, products, and a culture that will continue to fulfil Gennova’s mission of transforming healthcare. With this stake acquisition, we simplify Gennova’s ownership, sharpen its strategic focus, and position it under Mr. Samit Mehta’s leadership for its next phase of growth in biologics and biosimilars.”

Future Outlook

Mr. Samit Mehta, Whole Time Director & CEO, Gennova Biopharmaceuticals Limited, said: “As part of the One Emcure framework, Gennova will continue to anchor the Group’s biologics and biosimilars capabilities. Our work will complement Emcure’s broader R&D and pipeline priorities, with a focus on execution, quality and disciplined development across our chosen therapy areas.” The transaction is not expected to have a material impact on Emcure’s consolidated financials or its capital allocation framework. The Company’s deleveraging trajectory, capex plans and R&D investment plans remain unchanged.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Emcure rises 13.4% over three months, with buying pressure holding steady. The business compounds revenue at 15.8% and profits at 20.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 81% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The business grows revenue at 15.8% and profits at 20.2%, with D/E of 0.22. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 1.84 premium is usually justified. Check Fundamentals of Emcure Pharmaceuticals Limited.

Emcure Pharmaceuticals Limited (EMCURE) breaks out with a +5% gain to ₹1884.0 on the NSE, clearing its 6-month resistance trendline. This move is driven by a technical breakout as the stock surpassed the key resistance level at ₹1731, marking an 8.1% increase. Emcure, a prominent player in the specialty and generic drug manufacturing sector, has shown resilience and growth potential, aligning with the positive momentum in the healthcare sector.

Technical setup — trendlines & DMA

From a technical perspective, Emcure Pharmaceuticals has established a robust 6-month trendline structure. The 6-month support trendline is positioned at ₹1751.43, with the current price sitting 7.04% above this level. The resistance trendline, previously at ₹1730.65, has been decisively broken, indicating strong upward momentum. The 50-DMA at ₹1690.8 is above the 200-DMA at ₹1501.0, signaling a bullish trend. The stock is currently trading in the upper third of its 52-week range, suggesting that a significant portion of the recent gains may already be priced in.

Fundamentals & business context

On the fundamental front, Emcure Pharmaceuticals presents a mixed picture. With a PE ratio of 36.7 and profit margins at 10.0%, the valuation appears stretched relative to current earnings. However, the revenue CAGR of 15.8% and profit CAGR of 20.2% over the past five years indicate strong growth potential. The low institutional holding of 5.5% suggests that the smart money is cautiously optimistic about the stock. There was no NSE catalyst today, making this move predominantly technical in nature.

Algorithmic scorecard

The overall algorithmic scorecard for Emcure Pharmaceuticals reflects a balanced view, with a slight tilt towards strong fundamentals and moderate technical indicators. The strongest signals come from the revenue and profit CAGRs, which are very good and excellent respectively, indicating robust business growth. Additionally, the very low debt levels and consistent revenue growth every year highlight strong financial health and business stability. On the weaker side, the thin profit margins of 10.0% leave little room for error, and the negligible dividend yield of 0.17% offers little income for investors. These factors should be carefully considered when evaluating the stock’s long-term potential.

Company outlook

Emcure Pharmaceuticals has provided a positive forward guidance for FY27. The company projects low to mid-teen revenue growth and expects an EBITDA margin expansion of 75 to 100 basis points. Growth is anticipated in Canada and Europe, driven by market share gains, new launches, and an expanded portfolio. The company plans to focus on organic growth, building its own brands, and launching R&D products. Specific plans include expanding Amphotericin B to Europe and other global markets in FY27, launching Bevacizumab in H1 FY27 pending approval, and seeking product registration for Gilead Lenacapavir in FY27. Capital expenditure is expected to be around INR 400-425 crores for FY27. Additionally, Emcure has partnered with Dr. Reddy’s for the semaglutide launch in Quebec, Canada.

Get all details on EMCURE — P&L, peers, shareholding and more on TradeAlone.